CTRI/2013/06/003788已完成1 期
Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in women with LOBC and LABC - Feasibility Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria:
- •-Unilateral breast cancer
- •-Large operable breast cancer/LOBC (T3N0M0 or T3N1M0) and Locally advanced breast cancer/LABC (T3N1-2M0; T2N2M0)
- •-Age <70 years
- •-Fit for CT
排除标准
- •Exclusion Criteria:
- •-Prior IB or EB
- •-Metastatic breast cancer
- •-Renal failure or deranged RFT
- •-Hypoparathyroidism
- •-Pregnant or lactating mothers or women of childbearing age not practicing contraception
- •-Patient on any of the following drugs: Magnesium-containing antacids, Digitalis, Phenytoin barbiturates, Thiazide diuretics.
- •-Previous history of other cancers except cured skin and cervical carcinoma in situ.
研究者
相似试验
已完成
3 期
Randomized controlled trial of neoadjuvant chemotherapy plus surgery versus neoadjuvant chemoradiotherapy plus surgery in patients with clinical stage IIB-III esophageal carcinoma (Subset analyses depending on the REG I expression in the tumor)thoracic esophageal cancerJPRN-UMIN000004707The cancer board of esophageal cancer in Akita University Hospital150
招募中
3 期
a phase 3 study of chemotherapy folowed by surgery and postoperative chemotherapy compared to initial surgery followed by chemotherapy in advanced ovarian cancerCTRI/2014/01/004363Sri Venkateswara Institute of Medical Sciences60
进行中（未招募）
3 期
eo Adjuvant Chemotherapy in Triple Negative Breast CancerCTRI/2012/07/002802Tata Memorial Centre
进行中（未招募）
1 期
Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of PembrolizumabThis trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3) compared to radiotherapy alone followed by surgical resectionMedDRA version: 20.0Level: PTClassification code 10024629Term: Liposarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001360-39-ITSARC110
进行中（未招募）
不适用
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2013-001494-24-ESEncore Clinical, Inc1,050